

Novoclem announces CEO Anne Whitaker to present at the BIO CEO & Investor Annual Conference on Monday February 12th, 2018



NEWS PROVIDED BY
Novoclem Therapeutics, Inc. →
10:00 ET

DURHAM, N.C., Feb. 8, 2018 /PRNewswire/ -- Novoclem Therapeutics, a preclinical-stage pharmaceutical company focused on helping people who suffer from severe respiratory diseases to breathe better and live life more fully, today announced that it will present at the Bio CEO & Investor Conference, to be held February 12th -13th at the New York Marriott Marquis.

Date: February 12, 2018

Time: 2:00PM EST

Venue: New York Marriott Marquis

Room: Brecht

Presenter: Anne Whitaker, CEO & President

About Biotech Showcase 2018

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

About Novoclem Therapeutics, Inc.

Novoclem Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, is initially focused on developing a nitric oxide based treatment for people living with cystic fibrosis and infected with *Pseudomonas aeruginosa*. The company anticipates submitting an Investigational New Drug application and initiating First in Human clinical trials in 2018. More info available at www.novoclem.com.

About KNOW Bio LLC

KNOW Bio, LLC, is a life science company committed to improving and extending people's lives by advancing the development and commercialization of its drug and device pipeline through wholly or majority owned subsidiary companies. Each subsidiary is focused on a specific therapeutic application where nitric oxide provides meaningful health benefit.

Forward-looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could

cause actual results to differ materially include: risks associated with the drug development process; reliance on key personnel; the early stage of our business; competition; and other risks described in other Company press releases and presentations. Novoclem Therapeutics assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Media Contact:

Darlene Dendy

1-919-270-5789

ddendy@novoclem.com

SOURCE Novoclem Therapeutics, Inc.

Related Links

<http://www.novoclem.com>